These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 28700545)

  • 21. Cystic fibrosis, ivacaftor, and the Arg117His-CFTR mutation.
    Accurso FJ
    Lancet Respir Med; 2015 Jul; 3(7):498-9. PubMed ID: 26170070
    [No Abstract]   [Full Text] [Related]  

  • 22. Mutation-specific therapy in cystic fibrosis: the earlier, the better.
    Tümmler B
    Lancet Respir Med; 2013 Oct; 1(8):591-592. PubMed ID: 24461654
    [No Abstract]   [Full Text] [Related]  

  • 23. Cystic fibrosis drug is not cost effective, says NICE.
    Gulland A
    BMJ; 2016 Jun; 353():i3409. PubMed ID: 27325384
    [No Abstract]   [Full Text] [Related]  

  • 24. Ivacaftor imaging response in cystic fibrosis.
    Hoare S; McEvoy S; McCarthy CJ; Kilcoyne A; Brady D; Gibney B; Gallagher CG; McKone EF; Dodd JD
    Am J Respir Crit Care Med; 2014 Feb; 189(4):484. PubMed ID: 24528318
    [No Abstract]   [Full Text] [Related]  

  • 25. A combination therapy for cystic fibrosis.
    Brodsky JL; Frizzell RA
    Cell; 2015 Sep; 163(1):17. PubMed ID: 26406363
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ivacaftor in a G551D homozygote with cystic fibrosis.
    Harrison MJ; Murphy DM; Plant BJ
    N Engl J Med; 2013 Sep; 369(13):1280-2. PubMed ID: 24066763
    [No Abstract]   [Full Text] [Related]  

  • 27. Resolution of Intestinal Histopathology Changes in Cystic Fibrosis after Treatment with Ivacaftor.
    Safe M; Gifford AJ; Jaffe A; Ooi CY
    Ann Am Thorac Soc; 2016 Feb; 13(2):297-8. PubMed ID: 26848606
    [No Abstract]   [Full Text] [Related]  

  • 28. [Combined administration of lumacaftor and ivacaftor as a causal therapeutic approach].
    Desch M
    Med Monatsschr Pharm; 2016 Jan; 39(1):42-4. PubMed ID: 26975180
    [No Abstract]   [Full Text] [Related]  

  • 29. New Treatment for Cystic Fibrosis.
    Aschenbrenner DS
    Am J Nurs; 2020 Feb; 120(2):21. PubMed ID: 31977412
    [No Abstract]   [Full Text] [Related]  

  • 30. [Causal therapy is available].
    Meißner T
    MMW Fortschr Med; 2016 Jun; 158(12):74. PubMed ID: 27324018
    [No Abstract]   [Full Text] [Related]  

  • 31. PharmGKB summary: ivacaftor pathway, pharmacokinetics/pharmacodynamics.
    Fohner AE; McDonagh EM; Clancy JP; Whirl Carrillo M; Altman RB; Klein TE
    Pharmacogenet Genomics; 2017 Jan; 27(1):39-42. PubMed ID: 27636560
    [No Abstract]   [Full Text] [Related]  

  • 32. The evidence for long-term benefits of restoration of CFTR function continues to grow.
    Boyle MP
    Am J Respir Crit Care Med; 2015 Oct; 192(7):774-6. PubMed ID: 26426780
    [No Abstract]   [Full Text] [Related]  

  • 33. Cystic Fibrosis: The Dawn of a New Therapeutic Era.
    Heltshe SL; Cogen J; Ramos KJ; Goss CH
    Am J Respir Crit Care Med; 2017 Apr; 195(8):979-984. PubMed ID: 27710011
    [No Abstract]   [Full Text] [Related]  

  • 34. Lumacaftor/ivacaftor (Orkambi) for cystic fibrosis.
    Med Lett Drugs Ther; 2016 Mar; 58(1491):41-2. PubMed ID: 27027688
    [No Abstract]   [Full Text] [Related]  

  • 35. Precision Medicine: At What Price?
    Ferkol T; Quinton P
    Am J Respir Crit Care Med; 2015 Sep; 192(6):658-9. PubMed ID: 26207804
    [No Abstract]   [Full Text] [Related]  

  • 36. Personalized medicine comes to cystic fibrosis.
    Am J Med Genet A; 2012 Feb; 158A(2):viii-ix. PubMed ID: 22266959
    [No Abstract]   [Full Text] [Related]  

  • 37. Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?
    Jones AM; Barry PJ
    Thorax; 2015 Jul; 70(7):615-6. PubMed ID: 26071414
    [No Abstract]   [Full Text] [Related]  

  • 38. Response.
    Durmowicz AG; Witzmann KA; Rosebraugh CJ; Chowdhury BA
    Chest; 2013 Oct; 144(4):1418-1419. PubMed ID: 24081359
    [No Abstract]   [Full Text] [Related]  

  • 39. Settlement reached over medicaid coverage of cystic fibrosis drug: Arkansas federal court case highlights medical necessity, high cost of targeted therapies.
    Am J Med Genet A; 2015 Apr; 167A(4):viii-ix. PubMed ID: 25820402
    [No Abstract]   [Full Text] [Related]  

  • 40. Resolution of cystic fibrosis-related diabetes with ivacaftor therapy.
    Hayes D; McCoy KS; Sheikh SI
    Am J Respir Crit Care Med; 2014 Sep; 190(5):590-1. PubMed ID: 25171312
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.